Andrea Gershon1, Graham Mecredy2, Ruth Croxford2, Teresa To2, Matthew B Stanbrook2, Shawn D Aaron2. 1. Institute for Clinical Evaluative Sciences (Gershon, Mecredy, Croxford, To, Stanbrook); Sunnybrook Health Sciences Centre (Gershon); Institute of Health Policy, Management and Evaluation (Gershon, Stanbrook) and Dalla Lana School of Public Health (To), University of Toronto; The Hospital for Sick Children (To); University Health Network (Stanbrook), Toronto, Ont.; Ottawa Hospital Research Institute (Aaron), University of Ottawa, Ottawa, Ont. andrea.gershon@ices.on.ca. 2. Institute for Clinical Evaluative Sciences (Gershon, Mecredy, Croxford, To, Stanbrook); Sunnybrook Health Sciences Centre (Gershon); Institute of Health Policy, Management and Evaluation (Gershon, Stanbrook) and Dalla Lana School of Public Health (To), University of Toronto; The Hospital for Sick Children (To); University Health Network (Stanbrook), Toronto, Ont.; Ottawa Hospital Research Institute (Aaron), University of Ottawa, Ottawa, Ont.
Abstract
BACKGROUND: A small number of people with chronic obstructive pulmonary disease (COPD) receive pulmonary function testing around the time of diagnosis. Because omitting testing increases misdiagnosis, we sought to determine whether health outcomes differed between patients whose COPD was diagnosed with or without pulmonary function testing. METHODS: We conducted a longitudinal population study of patients with physician-diagnosed COPD from 2005 to 2012 using health administrative data from Ontario, Canada. We assessed whether having pulmonary function testing around the time of diagnosis was associated with the composite outcome of admission to hospital for COPD or all-cause death, using adjusted survival analysis. RESULTS: Chronic obstructive pulmonary disease was diagnosed in 68 898 patients during the study period; 41.2% of patients received peridiagnostic pulmonary function testing. In adjusted analysis, patients who underwent testing were less likely to die or be admitted to hospital for COPD (adjusted hazard ratio [HR] 0.91, 95% confidence interval [CI] 0.89-0.94) and were more likely to be prescribed an inhaled long-acting bronchodilator than patients who did not undergo testing. Subgroup analysis suggested that the association of testing and outcomes was confined to patients with COPD diagnosed in the ambulatory care setting (adjusted HR 0.80, 95% CI 0.76-0.84). INTERPRETATION: Confirmation of a COPD diagnosis using pulmonary function testing is associated with a decreased risk of death and admission to hospital for COPD. In ambulatory patients, this effect may be from increased use of appropriate COPD medications. The findings of this study validate current guideline recommendations that encourage pulmonary function testing for diagnosis in all patients with suspected COPD.
BACKGROUND: A small number of people with chronic obstructive pulmonary disease (COPD) receive pulmonary function testing around the time of diagnosis. Because omitting testing increases misdiagnosis, we sought to determine whether health outcomes differed between patients whose COPD was diagnosed with or without pulmonary function testing. METHODS: We conducted a longitudinal population study of patients with physician-diagnosed COPD from 2005 to 2012 using health administrative data from Ontario, Canada. We assessed whether having pulmonary function testing around the time of diagnosis was associated with the composite outcome of admission to hospital for COPD or all-cause death, using adjusted survival analysis. RESULTS:Chronic obstructive pulmonary disease was diagnosed in 68 898 patients during the study period; 41.2% of patients received peridiagnostic pulmonary function testing. In adjusted analysis, patients who underwent testing were less likely to die or be admitted to hospital for COPD (adjusted hazard ratio [HR] 0.91, 95% confidence interval [CI] 0.89-0.94) and were more likely to be prescribed an inhaled long-acting bronchodilator than patients who did not undergo testing. Subgroup analysis suggested that the association of testing and outcomes was confined to patients with COPD diagnosed in the ambulatory care setting (adjusted HR 0.80, 95% CI 0.76-0.84). INTERPRETATION: Confirmation of a COPD diagnosis using pulmonary function testing is associated with a decreased risk of death and admission to hospital for COPD. In ambulatory patients, this effect may be from increased use of appropriate COPD medications. The findings of this study validate current guideline recommendations that encourage pulmonary function testing for diagnosis in all patients with suspected COPD.
Authors: Mats Arne; Karin Lisspers; Björn Ställberg; Gunnar Boman; Hans Hedenström; Christer Janson; Margareta Emtner Journal: Respir Med Date: 2010-04 Impact factor: 3.415
Authors: Meilan K Han; Min Gayles Kim; Russell Mardon; Phil Renner; Sean Sullivan; Gregory B Diette; Fernando J Martinez Journal: Chest Date: 2007-06-05 Impact factor: 9.410
Authors: Barbara P Yawn; Paul L Enright; Robert F Lemanske; Elliot Israel; Wilson Pace; Peter Wollan; Homer Boushey Journal: Chest Date: 2007-06-05 Impact factor: 9.410
Authors: Lee Gazourian; William B Thedinger; Shawn M Regis; Elizabeth J Pagura; Lori Lyn Price; Melissa Gawlik; Cristina F Stefanescu; Carla Lamb; Kimberly M Rieger-Christ; Harpreet Singh; Marcel Casasola; Alexander R Walker; Arashdeep Rupal; Avignat S Patel; Carolyn E Come; Ava M Sanayei; William P Long; Giulia S Rizzo; Andrea B McKee; George R Washko; Raul San Jose Estepar; Christoph Wald; Brady J McKee; Carey C Thomson; Timothy N Liesching Journal: Respir Med Date: 2020-11-20 Impact factor: 3.415
Authors: Sahar Mansoor; Zaid Obaida; Lorna Ballowe; Amanda R Campbell; James T Patrie; Timothy D Byrum; Yun M Shim Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-01-08
Authors: Don Thiwanka Wijeratne; Ahmad Housin; Katherine Lajkosz; M Diane Lougheed; Ping Yu Xiong; David Barber; Katharine M Doliszny; Stephen L Archer Journal: Pulm Circ Date: 2022-02-04 Impact factor: 2.886
Authors: Lee Gazourian; Shawn M Regis; Elizabeth J Pagura; Lori Lyn Price; Melissa Gawlik; Carla Lamb; Kimberly M Rieger-Christ; William B Thedinger; Ava M Sanayei; William P Long; Cristina F Stefanescu; Giulia S Rizzo; Avignat S Patel; Carolyn E Come; Carey C Thomson; Victor Pinto-Plata; Katrina Steiling; Andrea B McKee; Christoph Wald; Brady J McKee; Timothy N Liesching Journal: Respir Med Date: 2021-07-12 Impact factor: 4.582
Authors: Valerie G Press; David H Au; Jean Bourbeau; Mark T Dransfield; Andrea S Gershon; Jerry A Krishnan; Richard A Mularski; Frank C Sciurba; Jamie Sullivan; Laura C Feemster Journal: Ann Am Thorac Soc Date: 2019-02